What's hot
View all perspectives
Dr. John Cush RheumNow
1 year 3 months ago
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.
Dr. John Cush RheumNow
1 year 3 months ago
Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T
Bella Mehta bella_mehta
1 year 3 months ago
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
Janet Pope Janetbirdope
1 year 3 months ago
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
PA Juge Juge_P_A
1 year 3 months ago
Oral presentation at #EULAR2024 about clustering #RA #ILD 🫁 @PhilippeDieude @jeffsparks @RaphaelBorie @bruno_crestani https://t.co/jz1unKIZmN
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Do the clinical features of axSpA patients with and without IBD differ?
In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.
Dr. John Cush RheumNow
1 year 3 months ago
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
Annals of the Rheumatic Diseases ARD_BMJ
1 year 3 months ago
New hypothesis are explored in #Sjogren
#EULAR2024
CB https://t.co/0glF5BGVO5
Annals of the Rheumatic Diseases ARD_BMJ
1 year 3 months ago
Major pathogenic characteristics of #Sjogren disease
#EULAR2024
CB https://t.co/3NeBBKIVT4
Annals of the Rheumatic Diseases ARD_BMJ
1 year 3 months ago
Did the patient fail on therapy or are the therapies failing the patient? 🤔
Difficult to to manage psoriatic arthritis: A suggested approach
#EULAR2024
NZ https://t.co/lYvXEX7dp3
Poster Hall